SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Sherlock S. Chronic hepatitis C. Dis Mon 1994; 40:117196.MEDLINE
  • 2
    Alter MJ, Hadler SC, Judson FN, Mares A, Alexander J, Hu PY, Miller JK, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990; 264:22312235.MEDLINE
  • 3
    Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, Krawczynski K, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group. Ann Intern Med 1995; 123:330337.MEDLINE
  • 4
    Patel A, Sherlock S, Dusheiko G, Scheuer P, Ellis LA, Ashrafzadeh P. Clinical course and histological correlations in post-transfusion hepatitis C: the Royal Free Hospital experience. Eur J Gastroenterol Hepatol 1991; 3:491495.
  • 5
    DiBisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis. Hepatology 1991; 14:969974.MEDLINE
  • 6
    Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332:14631466.MEDLINE
  • 7
    Choo Q-L, Richman KH, Han JH, Berger K, Lee C, Dong C, Gallegos C, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA 1991; 88:24512455.MEDLINE
  • 8
    Ogata N, Alter HJ, Miller RH, Purcell RH. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc Natl Acad Sci USA 1991; 88:33923396.MEDLINE
  • 9
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321:15011506.MEDLINE
  • 10
    Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995; 15:8291.MEDLINE
  • 11
    Pestka SS, Langer JA, Zoon KC, Samuel KC. Interferons and their actions. Annu Rev Biochem 1987; 56:727777.MEDLINE
  • 12
    Gewert D, Finter NB. Antiviral effects of interferons: studies in animals and at the cellular level. In: BaronS, CoppenhaverDH, DianzaniF, FleischmannWR, HughesTK, KlimpelGR, NieselDW, StantonGJ, TyringSK, eds. Interferon Principles and Medical Applications. Galveston: University of Texas, 1992;289297.
  • 13
    Shindo M, DiBisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon. Hepatology 1992; 15:10131016.MEDLINE
  • 14
    Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, DiNapoli A, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon α-2b. Hepatology 1993; 18:13001305.MEDLINE
  • 15
    Blatt LM, Davis JM, Klein SB, Taylor MW. The biologic activity and molecular characterization of a novel synthetic interferon-alpha species, consensus interferon. J Interferon Cytokine Res 1996; 16:489499.MEDLINE
  • 16
    Alton K, Stabinsky Y, Richards R, Ferguson B, Goldstein L, Altrock B, Miller L. Production, characterization and biological effects of recombinant DNA derived human IFN-α and IFN-gamma analogs. In: De Maeyer, E SchellekensH, eds. The Biology of the Interferon System. 2nd ed. Amsterdam: Elsevier Science Publishers, 1983;119128.
  • 17
    Tong M, Reddy KR, Lee WM, Pockros PJ, Hoefs CJ, Keeffe EB, Hollinger FB, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Hepatology 1997;26:747754.MEDLINE
  • 18
    Alberti A, Chenello L, Noverta F, Cavalletto L, De Salvo G. Retreatment with interferon; proceedings of the NIH Consensus Development Conference on Management of Hepatitis C. 3 Suppl Hepatology 1997; 26:13751425.
  • 19
    Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993; 74:10931102.MEDLINE
  • 20
    Simmonds P, Alberti P, Alter HJ, Bonino F, Bradley DW, Brechot C, Brouwer JT, et al. A proposed system for the nomenclature of hepatitis C viral genotypes [Letter] Hepatology 1994; 19:13211324.MEDLINE
  • 21
    Picciotto A, Brizzolara R, Campo N, Poggi G, Sinelli N, DeConca V, Giudici-Cipriani A, et al. Two year interferon retreatment may induce a sustained response in relapsing patients with chronic hepatitis C [Abstract] Hepatology 1996; 24:273A.
  • 22
    Payen JL, Izopet J, Galindo V, Zarski JP, Seigneurin JM, Dussaix E, Langlois C, et al. A comparison of three interferon alfa-2b regimens for retreatment (RTT) of patients with chronic hepatitis C with prior complete response followed by relapse; a controlled, randomized trial [Abstract] Hepatology 1996; 24:273A.
  • 23
    Chow WC, Marcellin P, Boyer N, Pouteau M, Castelnau C, Degos F, Maghinici C, et al. Interferon retreatment in chronic hepatitis C (CHC) patients after a standard course of interferon therapy [Abstract] Hepatology 1996; 24:274A.
  • 24
    Marcellin P, Pouteau M, Boyer N, Castelnau C, Erlinger S, Benhamou JP. Retreatment with recombinant interferon-α in patients with chronic hepatitis C [Letter] J Infect Dis 1993; 167:780781.MEDLINE
  • 25
    Toyoda H, Nakano S, Takeda I, Kumada T, Sugiyama K, Osada T, Kiriyama S, et al. Retreatment of chronic hepatitis C with interferon. Am J Gastroenterol 1994; 89:14531457.MEDLINE
  • 26
    Weiland O, Zhang Y-Y, Widell A. Serum HCV RNA levels in patients with chronic hepatitis C given a second course of interferon alpha-2b treatment after relapse following initial treatment. Scand J Infect Dis 1993; 25:2530.MEDLINE
  • 27
    Marriott E, Quiroga JA, Carreno V. Retreatment of chronic hepatitis C with interferon-α J Infect Dis 1992; 166:12001201.MEDLINE
  • 28
    Pockros PJ, Tong MJ, Lee WM, van Leeuwen DJ, Keeffe E, Bala K, Killenberg PG, et al. Relationship between biochemical and virological response to type 1 interferon therapy of chronic HCV infection [Abstract] Hepatology 1996; 24:113A.
  • 29
    Bresci G, Parisi G, Banti S, Capzia A. Re-treatment of interferon-resistant patients with chronic hepatitis C with interferon-α J Viral Hepatitis 1995; 2:155158.
  • 30
    Giudici-Cipriani A, Ponassi I, Varagona G, Marenco G, Grasso A, Menardo G, DeConca V, et al. Re-treatment of patients with chronic hepatitis C non-responders to a first interferon course: analysis of a large patient cohort [Abstract] Hepatology 1996; 24:273A.
  • 31
    d'Aquino M, Tempesta D, Bibiani S, Vianello G, Pipan C, Bellati G, Colloredo G, et al. Chronic hepatitis C: analysis of factors which influence the response to interferon therapy proven to be useful to optimize a second course [Abstract] Hepatology 1996; 24:498A.
  • 32
    Vial T, Descotes J. Clinical toxicity of the interferons. Drug Saf 1994; 10:115150.MEDLINE
  • 33
    Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis 1989; 9:273277.MEDLINE
  • 34
    Schvarcz R, Glaumann H, Weiland O, Norkrans G, Wejstal R, Fryden A. Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: Long-term outcome and effect of increased interferon doses in non-responders. Scand J Infect Dis 1991; 23:413420.MEDLINE